Therapeutic ReviewCALCIUM EDTA (EDETATE CALCIUM DISODIUM)
Section snippets
Pharmacokinetic and Pharmacodynamic Effects
As calcium is vital for muscle contraction, the therapeutic form of EDTA is manufactured as calcium EDTA to avoid unnecessary chelation of calcium from the sarcoplasmic reticulum. Instead, toxic metals such as lead and zinc, which have higher stability constants, will replace the Ca2+ ligand.1 Based on initial studies performed in laboratory rats, only 2% to 18% of EDTA is absorbed orally, whereas 95% to 98% is absorbed via parenteral administration (e.g., intramuscular, intravenous, and
Birds
Raptors commonly develop heavy metal toxicity through exposure to lead shot. Primary exposure occurs when the bird is shot directly with the pellet. Secondary exposure occurs when the animal consumes a prey item that has discrete heavy metal present or a stored concentration in its tissues. Secondary exposure will typically result in heavy metal being found within the gastrointestinal tract versus the pellet being located in the wing or shoulder girdle. Waterfowl usually ingest metallic items
Common Preparations Used in Veterinary Medicine
The FDA-approved human-labeled product is Edetate Calcium Disodium Injection Solution (Calcium Disodium Versenate): 200 mg/mL in 5 mL amps (1 g/amp). This product is manufactured by Valeant Pharmaceuticals International. The manufacturer recommends, when administering intravenously, to dilute the product to 2 to 4 mg/mL with 0.9% NaCl or 5% dextrose. If given intramuscularly, the manufacturer recommends adding 1 mL of lidocaine HCl 1% to each milliliter injected.17 Currently, there are no commercial
Summary
Calcium EDTA is commonly used for the treatment of heavy metal toxicity in humans and veterinary patients. A small number of research studies performed in avian species show a therapeutic benefit to parenterally administered 30 to 100 mg/kg CaEDTA every 12 to 24 hours. Although therapeutic level PK/PD studies in companion mammals are lacking, resolution of clinical signs and blood work abnormalities have been reported when 25 to 30 mg/kg is parenterally administered or concurrently administered
References (17)
- et al.
Metabolism of C14-labeled ethylenediamine-tetraacetic acid in the rat
J Biol Chem
(1953) - et al.
Influence of chelating agents on the gastrointestinal absorption of lead
Toxicol Appl Pharmacol
(1975) The effects of chelating agents on the tissue distribution and excretion of lead
Toxicol Appl Pharmacol
(1971)- et al.
Teratogenic effect of calcium edetate (CaEDTA) in rats and the protective effect of zinc
Toxicol Appl Pharmacol
(1986) - et al.
Chelation in metal intoxication
Int J Environ Res Public Health
(2010) - et al.
An evaluation of the nephrotoxicity of ethylenediaminetetraacetate and diethylenetriaminepentacetate in the rat
Toxicol Appl Pharmacol
(1967) - et al.
Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy
J Am Med Assoc
(1956) - et al.
Teratogenesis studies with EDTA and its salts in rats
Toxicol Appl Pharmacol
(1981)
Cited by (2)
Research progress in oxidative stress mechanism and antioxidant treatment of lead poisoning
2020, Journal of Xinxiang Medical University